More
- Topic1/3
19k Popularity
11k Popularity
20k Popularity
7k Popularity
3k Popularity
- Pin
- 🎊 ETH Deposit & Trading Carnival Kicks Off!
Join the Trading Volume & Net Deposit Leaderboards to win from a 20 ETH prize pool
🚀 Climb the ranks and claim your ETH reward: https://www.gate.com/campaigns/site/200
💥 Tiered Prize Pool – Higher total volume unlocks bigger rewards
Learn more: https://www.gate.com/announcements/article/46166
- 📢 ETH Heading for $4800? Have Your Say! Show Off on Gate Square & Win 0.1 ETH!
The next bull market prophet could be you! Want your insights to hit the Square trending list and earn ETH rewards? Now’s your chance!
💰 0.1 ETH to be shared between 5 top Square posts + 5 top X (Twitter) posts by views!
🎮 How to Join – Zero Barriers, ETH Up for Grabs!
1.Join the Hot Topic Debate!
Post in Gate Square or under ETH chart with #ETH Hits 4800# and #ETH# . Share your thoughts on:
Can ETH break $4800?
Why are you bullish on ETH?
What's your ETH holding strategy?
Will ETH lead the next bull run?
Or any o
- 🧠 #GateGiveaway# - Crypto Math Challenge！
💰 $10 Futures Voucher * 4 winners
To join:
1️⃣ Follow Gate_Square
2️⃣ Like this post
3️⃣ Drop your answer in the comments
📅 Ends at 4:00 AM July 22 (UTC)
- 🎉 [Gate 30 Million Milestone] Share Your Gate Moment & Win Exclusive Gifts!
Gate has surpassed 30M users worldwide — not just a number, but a journey we've built together.
Remember the thrill of opening your first account, or the Gate merch that’s been part of your daily life?
📸 Join the #MyGateMoment# campaign!
Share your story on Gate Square, and embrace the next 30 million together!
✅ How to Participate:
1️⃣ Post a photo or video with Gate elements
2️⃣ Add #MyGateMoment# and share your story, wishes, or thoughts
3️⃣ Share your post on Twitter (X) — top 10 views will get extra rewards!
👉
Fuhong Hanlin: Grants Alvogen Korea exclusive license for Hans.
Jin10 Data reported on April 25 that Fuhong Hanlin announced that the company has entered into a licensing protocol with Alvogen Korea Co., Ltd., granting it exclusive rights to commercialize Hanshuang (Srilumab injection) in South Korea. Under the protocol, Alvogen Korea will pay an upfront payment of $5 million, with regulatory milestone payments not exceeding $9.5 million, commercial sales milestone payments not exceeding $97.5 million, and tiered royalties calculated based on annual net sales ranging from 18% to 25%. The licensing protocol will take effect from the date of signing and will initially last until the 10th anniversary of the first commercial sale of the licensed product.